EBITDA Summary of Azitra, Inc.

Azitra, Inc.'s latest annual EBITDA in 2023 was -10.67 Million USD , down -6.49% from previous year.
Azitra, Inc.'s latest quarterly EBITDA in 2024 Q2 was -2.54 Million USD , up 10.68% from previous quarter.
Azitra, Inc. reported an annual EBITDA of -10.02 Million USD in 2022, down -11.11% from previous year.
Azitra, Inc. reported an annual EBITDA of -8.78 Million USD in 2021, down 0.0% from previous year.
Azitra, Inc. reported a quarterly EBITDA of -2.84 Million USD for 2024 Q1, down -21.06% from previous quarter.
Azitra, Inc. reported a quarterly EBITDA of -1.83 Million USD for 2023 Q3, up 56.96% from previous quarter.

Annual EBITDA Chart of Azitra, Inc. (2023 - 2021)

Name	EBITDA	EBITDA Difference
AIM ImmunoTech Inc.	-31.67 Million USD	66.307%
Ampio Pharmaceuticals, Inc.	- USD	Infinity%
Armata Pharmaceuticals, Inc.	-39.91 Million USD	73.262%
Actinium Pharmaceuticals, Inc.	-51.13 Million USD	79.125%
Can-Fite BioPharma Ltd.	-8.18 Million USD	-30.479%
Chromocell Therapeutics Corporation	-6.86 Million USD	-55.534%
Calidi Biotherapeutics, Inc.	-28.6 Million USD	62.681%
CEL-SCI Corporation	-27.56 Million USD	61.274%
iBio, Inc.	-14.02 Million USD	23.877%
Lineage Cell Therapeutics, Inc.	-24.73 Million USD	56.846%
MAIA Biotechnology, Inc.	-20.18 Million USD	47.116%
Matinas BioPharma Holdings, Inc.	-22.82 Million USD	53.239%
Navidea Biopharmaceuticals, Inc.	-13.87 Million USD	23.077%
NovaBay Pharmaceuticals, Inc.	-4.8 Million USD	-122.358%
NanoViricides, Inc.	-7.75 Million USD	-37.593%
Oragenics, Inc.	-20.87 Million USD	48.877%
BiomX Inc.	-22.81 Million USD	53.219%
BiomX Inc.	-22.81 Million USD	53.219%
Protalix BioTherapeutics, Inc.	11.65 Million USD	191.608%
Palatin Technologies, Inc.	-29.03 Million USD	63.235%
Scorpius Holdings, Inc.	-35.08 Million USD	69.577%